{"id":"https://openalex.org/W4281560766","doi":"https://doi.org/10.2217/fon-2022-0310","title":"A Real-World US Study of Recurrence Risks using Combined Clinicopathological Features in HR-Positive, HER2-Negative Early Breast Cancer","display_name":"A Real-World US Study of Recurrence Risks using Combined Clinicopathological Features in HR-Positive, HER2-Negative Early Breast Cancer","publication_year":2022,"publication_date":"2022-05-25","ids":{"openalex":"https://openalex.org/W4281560766","doi":"https://doi.org/10.2217/fon-2022-0310","pmid":"https://pubmed.ncbi.nlm.nih.gov/35611679"},"language":"en","primary_location":{"id":"doi:10.2217/fon-2022-0310","doi":"https://doi.org/10.2217/fon-2022-0310","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon-2022-0310","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.2217/fon-2022-0310","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5043605449","display_name":"Kristin M. Sheffield","orcid":"https://orcid.org/0000-0003-3940-1795","observed_orcids":["https://orcid.org/0000-0003-3940-1795"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristin M Sheffield","raw_affiliation_strings":["Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA"],"raw_orcid":"https://orcid.org/0000-0003-3940-1795","affiliations":[{"raw_affiliation_string":"Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056462668","display_name":"Jessica Peachey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica R Peachey","raw_affiliation_strings":["Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029359855","display_name":"Michael W. Method","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I4210096123","display_name":"ImmunoGen (United States)","ror":"https://ror.org/00scb2f23","country_code":"US","type":"company","lineage":["https://openalex.org/I4210096123"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Method","raw_affiliation_strings":["Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA","ImmunoGen,\rWaltham,\rMA 02451,\rUSA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"ImmunoGen,\rWaltham,\rMA 02451,\rUSA","institution_ids":["https://openalex.org/I4210096123"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018512578","display_name":"Brenda R. Grimes","orcid":"https://orcid.org/0000-0002-7883-7957","observed_orcids":["https://orcid.org/0000-0002-7883-7957"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brenda R Grimes","raw_affiliation_strings":["Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA"],"raw_orcid":"https://orcid.org/0000-0002-7883-7957","affiliations":[{"raw_affiliation_string":"Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003889471","display_name":"Jacqueline Brown","orcid":"https://orcid.org/0000-0002-1130-6414","observed_orcids":["https://orcid.org/0000-0002-1130-6414"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacqueline Brown","raw_affiliation_strings":["Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082016998","display_name":"Kim R. Saverno","orcid":"https://orcid.org/0000-0002-3421-3755","observed_orcids":["https://orcid.org/0000-0002-3421-3755"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]},{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kim Saverno","raw_affiliation_strings":["Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA","US Medical Affairs,Incyte Corporation,\rWilmington,\rDE 19803,\rUSA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"US Medical Affairs,Incyte Corporation,\rWilmington,\rDE 19803,\rUSA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013007948","display_name":"Tomoko Sugihara","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210105783","display_name":"Syneos Health (United States)","ror":"https://ror.org/01r74wp43","country_code":"US","type":"company","lineage":["https://openalex.org/I4210105783"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tomoko Sugihara","raw_affiliation_strings":["Syneos Health,\rMorrisville,\rNC 27560,\rUSA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Syneos Health,\rMorrisville,\rNC 27560,\rUSA","institution_ids":["https://openalex.org/I4210105783"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086108457","display_name":"Zhanglin Lin Cui","orcid":"https://orcid.org/0000-0002-7034-0946","observed_orcids":["https://orcid.org/0000-0002-7034-0946"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhanglin Lin Cui","raw_affiliation_strings":["Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA"],"raw_orcid":"https://orcid.org/0000-0002-7034-0946","affiliations":[{"raw_affiliation_string":"Eli Lilly and Company,\rIndianapolis,\rIN 46225,\rUSA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021935697","display_name":"Kimberley T. Lee","orcid":"https://orcid.org/0000-0002-3346-0885","observed_orcids":["https://orcid.org/0000-0002-3346-0885"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kimberley T Lee","raw_affiliation_strings":["Departments of Breast Oncology and Health Outcomes and Behavior,H. Lee Moffitt Cancer Center & Research Institute,\rTampa,\rFL 33612,\rUSA"],"raw_orcid":"https://orcid.org/0000-0002-3346-0885","affiliations":[{"raw_affiliation_string":"Departments of Breast Oncology and Health Outcomes and Behavior,H. Lee Moffitt Cancer Center & Research Institute,\rTampa,\rFL 33612,\rUSA","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":8.6119,"has_fulltext":false,"cited_by_count":68,"citation_normalized_percentile":{"value":0.98654369,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"18","issue":"21","first_page":"2667","last_page":"2682"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.5654000043869019,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.5654000043869019,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.43070000410079956,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/early-breast-cancer","display_name":"early breast cancer","score":0.777999997138977},{"id":"https://openalex.org/keywords/hormone-receptor-positive","display_name":"hormone receptor-positive","score":0.7789999842643738},{"id":"https://openalex.org/keywords/her2-negative","display_name":"HER2-negative","score":0.9309999942779541},{"id":"https://openalex.org/keywords/risk-of-recurrence","display_name":"recurrence risk","score":0.902999997138977},{"id":"https://openalex.org/keywords/high-risk-patients","display_name":"high-risk patients","score":0.5870000123977661},{"id":"https://openalex.org/keywords/invasive-disease-free-survival","display_name":"invasive disease-free survival","score":0.9039999842643738},{"id":"https://openalex.org/keywords/distant-recurrence-free-survival","display_name":"distant recurrence-free survival","score":0.9850000143051147},{"id":"https://openalex.org/keywords/lymph-node-metastasis","display_name":"lymph node metastasis","score":0.7289999723434448},{"id":"https://openalex.org/keywords/ki-67","display_name":"Ki-67","score":0.8889999985694885},{"id":"https://openalex.org/keywords/tumor-grade","display_name":"tumor grade","score":0.7400000095367432},{"id":"https://openalex.org/keywords/abemaciclib","display_name":"abemaciclib","score":0.8399999737739563},{"id":"https://openalex.org/keywords/monarche-trial","display_name":"monarchE trial","score":0.6600000262260437},{"id":"https://openalex.org/keywords/electronic-health-records","display_name":"electronic health records","score":0.781000018119812}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8850957155227661},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.8117531538009644},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.7619398832321167},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7344045639038086},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7205939292907715},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.6513568162918091},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4983963966369629},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.49118778109550476},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4445624351501465},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.21571388840675354},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D016016","descriptor_name":"Proportional Hazards Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2217/fon-2022-0310","doi":"https://doi.org/10.2217/fon-2022-0310","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon-2022-0310","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},{"id":"pmid:35611679","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35611679","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future oncology (London, England)","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.2217/fon-2022-0310","doi":"https://doi.org/10.2217/fon-2022-0310","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon-2022-0310","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":59,"referenced_works":["https://openalex.org/W71213456","https://openalex.org/W1497013683","https://openalex.org/W1529243395","https://openalex.org/W1531348775","https://openalex.org/W1924240366","https://openalex.org/W1961026612","https://openalex.org/W1999130958","https://openalex.org/W2080545389","https://openalex.org/W2096864872","https://openalex.org/W2103063413","https://openalex.org/W2117228403","https://openalex.org/W2134807611","https://openalex.org/W2136839015","https://openalex.org/W2158997529","https://openalex.org/W2165597190","https://openalex.org/W2203649236","https://openalex.org/W2279220517","https://openalex.org/W2318605753","https://openalex.org/W2417623773","https://openalex.org/W2470554684","https://openalex.org/W2495668504","https://openalex.org/W2572585609","https://openalex.org/W2728077452","https://openalex.org/W2762092204","https://openalex.org/W2767600184","https://openalex.org/W2768080316","https://openalex.org/W2795120383","https://openalex.org/W2799954804","https://openalex.org/W2800158081","https://openalex.org/W2804210712","https://openalex.org/W2806471440","https://openalex.org/W2885668565","https://openalex.org/W2898952791","https://openalex.org/W2901314939","https://openalex.org/W2905545945","https://openalex.org/W2912834234","https://openalex.org/W2917102036","https://openalex.org/W2923800831","https://openalex.org/W2938876221","https://openalex.org/W2956119214","https://openalex.org/W3011104356","https://openalex.org/W3011119029","https://openalex.org/W3014998117","https://openalex.org/W3087501542","https://openalex.org/W3087520429","https://openalex.org/W3110569062","https://openalex.org/W3111725766","https://openalex.org/W3112570855","https://openalex.org/W3120241209","https://openalex.org/W3128646645","https://openalex.org/W3130416374","https://openalex.org/W3131900383","https://openalex.org/W3133130976","https://openalex.org/W3148345241","https://openalex.org/W3162883085","https://openalex.org/W3165576985","https://openalex.org/W3206169364","https://openalex.org/W3215275071","https://openalex.org/W4200029460"],"related_works":["https://openalex.org/W4411598255","https://openalex.org/W4410630424","https://openalex.org/W4214655767","https://openalex.org/W4407559495","https://openalex.org/W3170766837","https://openalex.org/W3087501542","https://openalex.org/W3088141713","https://openalex.org/W3110611197","https://openalex.org/W6958670048","https://openalex.org/W4412699691"],"abstract_inverted_index":{"Aim:":[0],"To":[1],"assess":[2],"invasive":[3],"disease-free":[4],"survival":[5,10],"(IDFS)":[6],"and":[7,50,65,82,100],"distant":[8],"relapse-free":[9],"(DRFS)":[11],"in":[12,123],"hormone":[13],"receptor-positive,":[14],"HER2-negative":[15],"early":[16],"breast":[17],"cancer":[18],"with":[19],"combined":[20],"clinicopathological":[21],"criteria":[22],"from":[23],"monarchE,":[24],"a":[25],"phase":[26],"III":[27],"study":[28],"of":[29,118],"abemaciclib.":[30],"Methods:":[31],"US":[32],"electronic":[33],"health":[34],"records":[35],"were":[36,109],"used":[37],"to":[38],"compare":[39],"outcomes":[40],"between":[41],"high-risk":[42,71,114,125],"(\u22654":[43],"lymph":[44,48],"nodes,":[45],"or":[46,56],"1\u20133":[47],"nodes":[49],"grade":[51],"3,":[52],"tumor":[53],"\u22655":[54],"cm":[55],"Ki-67":[57],"\u226520%)":[58],"versus":[59],"nonhigh-risk":[60,87],"groups":[61],"using":[62],"Kaplan\u2013Meier":[63],"methods":[64],"Cox":[66],"regression":[67],"models.":[68],"Results:":[69],"The":[70],"group":[72,88],"(n":[73,89],"=":[74,90],"557)":[75],"was":[76,120],"at":[77],"higher":[78,111],"risk":[79],"for":[80,112,130],"IDFS":[81,92],"DRFS":[83,101],"events":[84,93,102],"than":[85],"the":[86,113,124,128],"3471).":[91],"(hazard":[94,103],"ratio:":[95,104],"3.07;":[96],"95%":[97,106],"CI:":[98,107],"2.45\u20133.83)":[99],"3.15;":[105],"2.49\u20133.97)":[108],"significantly":[110],"group.":[115],"Conclusion:":[116],"Risk":[117],"recurrence":[119],"three-times":[121],"greater":[122],"group,":[126],"highlighting":[127],"need":[129],"better":[131],"therapies.":[132]},"counts_by_year":[{"year":2026,"cited_by_count":15},{"year":2025,"cited_by_count":20},{"year":2024,"cited_by_count":19},{"year":2023,"cited_by_count":12},{"year":2022,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-05-27T00:00:00"}